Abstract:New drugs are urgently needed for the treatment of human African trypanosomiasis (HAT). In line with our quest for novel inhibitors of trypanosomes, a small library of analogs of the antitrypanosomal hit (MMV675968) available at MMV as solid materials was screened for antitrypanosomal activity. In silico exploration of two potent antitrypanosomal structural analogs (7-MMV1578647 and 10-MMV1578445) as inhibitors of dihydrofolate reductase (DHFR) was achieved, together with elucidation of other antitrypanosomal modes of action. In addition, they were assessed in vitro for tentative inhibition of DHFR in a crude trypanosome extract. Their ADMET properties were also predicted using dedicated software. Overall, the two diaminoquinazoline analogs displayed approximately 40-fold and 60-fold more potency and selectivity in vitro than the parent hit, respectively (MMV1578445 (10): IC50 = 0.045 μM, SI = 1737; MMV1578467 (7): IC50 = 0.06 μM; SI = 412). Analogs 7 and 10 were also strong binders of the DHFR enzyme in silico, in all their accessible protonation states, and interacted with key DHFR ligand recognition residues Val32, Asp54, and Ile160. They also exhibited significant activity against trypanosome protein isolate. MMV1578445 (10) portrayed fast and irreversible trypanosome growth arrest between 4–72 h at IC99. Analogs 7 and 10 induced in vitro ferric iron reduction and DNA fragmentation or apoptosis induction, respectively. The two potent analogs endowed with predicted suitable physicochemical and ADMET properties are good candidates for further deciphering their potential as starting points for new drug development for HAT.

Lead Optimization of the 5-Phenylpyrazolopyrimidinone NPD-2975 toward Compounds with Improved Antitrypanosomal Efficacy

Discovery of 5-Phenylpyrazolopyrimidinone Analogs as Potent Antitrypanosomal Agents with In Vivo Efficacy

Hit-to-lead optimization of novel benzimidazole phenylacetamides as broad spectrum trypanosomacides

Cell-based Optimization of Novel Benzamides As Potential Antimalarial Leads

Tractable Quinolone Hydrazides Exhibiting Sub‐Micromolar and Broad Spectrum Antitrypanosomal Activities

Structural Optimization of BIPPO Analogs as Potent Antimalarials

Discovery and Optimization of a Novel Carboxamide Scaffold with Selective Antimalarial Activity

Design and Synthesis of 1,3-Diarylpyrazoles and Investigation of Their Cytotoxicity and Antiparasitic Profile

Pd-catalyzed C–C and C–N cross-coupling reactions in 2-aminothieno[3,2-d]pyrimidin-4(3H)-one series for antiplasmodial pharmacomodulation

Preliminary Structure–Activity Relationship Study of the MMV Pathogen Box Compound MMV675968 (2,4-Diaminoquinazoline) Unveils Novel Inhibitors of Trypanosoma brucei brucei

3-(Oxazolo[4,5-b]pyridin-2-yl)anilides as a novel class of potent inhibitors for the kinetoplastid Trypanosoma brucei, the causative agent for human African trypanosomiasis

Design and Synthesis of Α-Phenoxy-n-sulfonylphenyl Acetamides As Trypanosoma Brucei Leucyl-tRNA Synthetase Inhibitors.

Optimization of diastereomeric dihydropyridines as antimalarials

Designing Antitrypanosomal and Antileishmanial BODIPY Derivatives: A Computational and In Vitro Assessment

Hit-to-lead optimization of novel phenyl imidazole carboxamides that are active against Leishmania donovani

Lead Optimization and Avoidance of Metabolic-perturbing Motif Developing Novel Diarylpyrimidines as Potent HIV-1 NNRTIs

Novel aroyl guanidine anti-trypanosomal compounds that exert opposing effects on parasite energy metabolism

Synthesis, design, and optimization of a potent and selective series of pyridylpiperazines as promising antimalarial agents

Investigation of Novel Isatinylhydantoin Derivatives as Potential Anti‐kinetoplastid Agents

Antitrypanosomal Chloronitrobenzamides

Novel pyrrolobenzoxaboroles: design, synthesis, and biological evaluation against Trypanosoma brucei.